Methods for identifying modulators of the IL-17 pathway

ES3074063T3Undetermined Publication Date: 2026-07-16JANSSEN PHARMA NV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
ES · ES
Patent Type
Patents
Current Assignee / Owner
JANSSEN PHARMA NV
Filing Date
2021-04-28
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

There is a need to identify inhibitors of the IL-17 pathway to develop therapeutic options for autoimmune diseases such as psoriasis, psoriatic arthritis, and multiple sclerosis, as current oral small molecule antagonists are lacking in clinical trials.

Method used

A method and kit for identifying agents that modulate the IL-17 pathway by contacting cells with IL-17 or T cell conditioned media, incubating with an agent, and detecting changes in G-CSF levels or gene expression in the cell supernatant or cell, indicating modulation of the pathway.

Benefits of technology

The method effectively identifies agents capable of modulating the IL-17 pathway, providing potential therapeutic options for autoimmune diseases by using small molecules, polypeptides, or polynucleotides as modulators.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000022_0000
    Figure 00000022_0000
  • Figure 00000023_0000
    Figure 00000023_0000
  • Figure 00000023_0001
    Figure 00000023_0001
Patent Text Reader

Abstract

Methods for identifying agents that modulate the interleukin-17 (IL-17) pathway are described. These methods utilize the detection of granulocyte colony-stimulating factor (G-CSF) in the cell supernatant and / or the detection of the expression level of a gene or gene panel in a cell treated with an agent. Probes capable of detecting a gene or gene panel and kits for identifying agents that modulate the IL-17 pathway are also described.
Need to check novelty before this filing date? Find Prior Art